Heron Therapeutics price target raised to $20 from $16 at JMP Securities JMP Securities increased its price target on Heron after the company reported higher than expected EPS and stated that its new post-surgical pain program is expected to have its first clinical data later this year. The firm recommends owning the stock ahead of what it believes will be upcoming catalysts.
Heron Therapeutics price target raised to $33 from $25 at JMP Securities After meeting with Heron's management, JMP Securities believes that momentum is building for the company's acute pain program. The firm expects data slated to be announced next quarter to eliminate the program's risk. It keeps an Outperform rating on the shares.